Biological Therapy-Induced Systemic Vasculitis.

Area of Science:

• Immunology
• Rheumatology
• Clinical Medicine

Background:

• Biologic therapies are crucial for autoimmune conditions.
• A rare side effect is the development of new autoimmune diseases.
• Understanding these induced diseases is vital for patient safety.

Purpose of the Study:

• To elucidate immunopathogenic mechanisms of biologics-induced autoimmune diseases.
• To characterize clinical and laboratory features of these conditions.
• To review treatment strategies and outcomes.

Main Methods:

• Systematic review of case reports and national registries (BIOGEAS, RABBIT, BSRBR-RA, BIOBADAVEN).
• Analysis of over 200 reported cases diagnosed via histopathology or ACR/Chapel Hill criteria.
• Evaluation of demographic, clinical, and treatment data.

Main Results:

• Over 200 cases reported, predominantly in females (75%) with a mean age of 48 years.
• Rheumatoid arthritis was the most common underlying condition (>50%).
• Onset typically occurred within 90 days; 75% resolved upon biologic discontinuation, though steroids were universally required. One death was recorded.

Conclusions:

• Biologics-induced autoimmune diseases are a recognized, albeit rare, complication.
• Early recognition and drug withdrawal are key to favorable outcomes.
• Further research into underlying mechanisms can refine management strategies.